GO:1904731 positive regulation of intestinal lipid absorption: Regulatory Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1904731 describes any process that activates or increases the frequency, rate or extent of intestinal lipid absorption, a biological process essential for dietary fat uptake and whole-body energy homeostasis.
• Intestinal lipid absorption is a multistep process involving emulsification, lipolysis, micelle formation, enterocyte uptake, intracellular trafficking, and chylomicron secretion; positive regulation can occur at any of these steps.
• Key regulatory signals include T cell cholesterol transport, adipocyte-derived factors, and gut microbial metabolites that modulate enterocyte lipid handling.
• Dysregulation of intestinal lipid absorption contributes to obesity, metabolic syndrome, and inflammatory bowel disease, making it a therapeutic target.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable causal dissection of genes that positively regulate this process.
• Understanding GO:1904731 supports development of interventions for dyslipidemia, obesity, and related metabolic disorders.
Description
Intestinal lipid absorption is the physiological process by which dietary fats are broken down, taken up by enterocytes, and delivered to the circulation as chylomicrons. The Gene Ontology term GO:1904731, positive regulation of intestinal lipid absorption, encompasses any molecular or cellular event that increases the frequency, rate, or extent of this absorption process. This term is critical for researchers studying energy balance, obesity, and metabolic disease because even modest changes in absorption efficiency can have systemic consequences. Recent studies have identified immune cells, adipocyte-derived signals, and microbial metabolites as unexpected regulators of intestinal lipid uptake. For example, T cell cholesterol transport was shown to link intestinal immune responses to dietary lipid absorption, highlighting a neuro-immune-metabolic axis. Similarly, adipocyte iron levels impinge on a fat-gut crosstalk to regulate intestinal lipid absorption and mediate protection from obesity. These findings underscore the importance of GO:1904731 in integrative physiology and disease. This article provides a research-grade overview of the definition, mechanisms, key genes, disease relevance, and experimental models for studying positive regulation of intestinal lipid absorption.
positive regulation of intestinal lipid absorption At A Glance
| GO ID | GO:1904731 |
|---|---|
| GO term | positive regulation of intestinal lipid absorption |
| Ontology | biological_process |
| Synonym | activation of intestinal lipid absorption; up regulation of intestinal lipid absorption; up-regulation of intestinal lipid absorption; upregulation of intestinal lipid absorption |
| Major function | Enhances the uptake and transport of dietary lipids across the intestinal epithelium |
| Related process | Intestinal lipid absorption (GO:0098856) |
| Regulatory direction | Positive (activating) |
| Taxon range | Metazoa |
| Cellular location | Enterocytes, lamina propria immune cells, adipocytes (systemic signals) |
What Is GO:1904731?
GO:1904731 is defined as any process that activates or increases the frequency, rate or extent of intestinal lipid absorption. In other words, it covers positive regulatory events that enhance the uptake of lipids from the intestinal lumen into enterocytes and their subsequent transport into the body. This includes signals from hormones, immune cells, adipocytes, and the microbiome that upregulate lipid transporters, chylomicron assembly, or lymphatic secretion.
Why Is positive regulation of intestinal lipid absorption Important in Cell Biology?
Positive regulation of intestinal lipid absorption is central to energy homeostasis and is implicated in obesity, insulin resistance, and cardiovascular disease. Understanding the molecular players that upregulate this process can reveal therapeutic targets for reducing fat uptake or improving lipid malabsorption. Moreover, the interplay between immune cells, adipocytes, and the gut microbiome in controlling lipid absorption highlights the integrative nature of metabolic regulation.
• Obesity and metabolic syndrome: enhanced intestinal lipid absorption contributes to positive energy balance and adiposity.
• Cardiovascular disease: increased absorption of cholesterol and fatty acids elevates circulating lipids and atherosclerosis risk.
• Inflammatory bowel disease: immune cell-derived signals can modulate lipid absorption, linking inflammation to metabolic dysfunction.
• Gut microbiome: microbial metabolites such as short-chain fatty acids and conjugated linoleic acid influence lipid absorption and immune responses.
• Therapeutic targeting: inhibitors of lipid absorption (e.g., ezetimibe) are used clinically, and new regulators are potential drug targets.
• Nutrigenomics: dietary fiber and other nutrients can modulate absorption, affecting animal and human health.
• Cystic fibrosis: CFTR modulators like lumacaftor/ivacaftor improve liver cholesterol metabolism but do not fully correct hypocholesterolemia, indicating complex regulation.
• Drug discovery: molecular docking and ADMET studies on PDE-5 inhibitors reveal off-target effects on lipid-related pathways.
What Happens During positive regulation of intestinal lipid absorption?
Luminal digestion and emulsification
In simple terms: Fats are broken into tiny droplets so enzymes can digest them.
Dietary triglycerides are emulsified by bile salts and hydrolyzed by pancreatic lipase into free fatty acids and monoglycerides. Positive regulation can increase the efficiency of this step by enhancing bile secretion or lipase activity, although direct evidence for regulatory events at this stage is limited.
Micelle formation and enterocyte uptake
In simple terms: Digested fats are packaged into micelles that enter intestinal cells.
Free fatty acids and monoglycerides form mixed micelles with bile salts, which facilitate their diffusion across the enterocyte brush border. Transporters such as CD36 and FATP4 mediate uptake. Positive regulation may upregulate these transporters or increase micelle stability.
Intracellular trafficking and chylomicron assembly
In simple terms: Inside the cell, fats are reassembled and packaged for export.
Inside enterocytes, fatty acids are re-esterified into triglycerides and packaged with apolipoproteins (e.g., APOB) into chylomicrons. Positive regulation can enhance the expression or activity of enzymes like MGAT and DGAT, or apolipoproteins, thereby increasing chylomicron formation.
Lymphatic secretion and systemic delivery
In simple terms: Packaged fats are released into lymph and then blood.
Chylomicrons are secreted into the lymphatic system via exocytosis and eventually enter the bloodstream. Positive regulation may increase secretion rate or lymphatic flow. T cell cholesterol transport has been shown to link immune signals to this step.
Systemic feedback from adipocytes and immune cells
In simple terms: Fat tissue and immune cells send signals that turn up absorption.
Adipocyte iron levels modulate a fat-gut crosstalk that regulates intestinal lipid absorption and protects against obesity. Gut microbial fatty acid isomerization can also modulate intraepithelial T cells, which in turn influence lipid absorption.
Key Genes Involved in GO:1904731 positive regulation of intestinal lipid absorption
The following genes and proteins have been implicated in positive regulation of intestinal lipid absorption based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CD36 | Fatty acid transporter on enterocytes | Mediates uptake of long-chain fatty acids; knockout reduces lipid absorption |
| FATP4 | Fatty acid transport protein | Enhances fatty acid uptake; potential target for obesity |
| APOB | Structural component of chylomicrons | Required for chylomicron assembly and secretion |
| MTTP | Microsomal triglyceride transfer protein | Essential for APOB lipidation; mutations cause abetalipoproteinemia |
| DGAT1 | Diacylglycerol acyltransferase | Catalyzes final step of triglyceride synthesis; knockout reduces lipid absorption |
| MGAT2 | Monoacylglycerol acyltransferase | Involved in triglyceride resynthesis in enterocytes |
| NPC1L1 | Cholesterol transporter | Mediates intestinal cholesterol uptake; target of ezetimibe |
| ABCG5/ABCG8 | Cholesterol efflux transporters | Limit cholesterol absorption; mutations cause sitosterolemia |
| T cells (e.g., CD4+) | Immune regulation of lipid absorption | T cell cholesterol transport links immune responses to dietary lipid absorption |
| Adipocyte-derived factors | Systemic regulation | Adipocyte iron levels impinge on fat-gut crosstalk to regulate absorption |
| Gut microbiota | Metabolite production | Microbial fatty acid isomerization modulates intraepithelial T cells |
| SCFAs | Microbial metabolites | Berberine regulates SCFA metabolism and alleviates colitis-associated tumorigenesis |
| Dietary fiber | Modulates intestinal microorganisms | Regulation of dietary fiber on intestinal microorganisms affects animal health |
| CFTR | Chloride channel | Lumacaftor/ivacaftor improves liver cholesterol metabolism in cystic fibrosis |
| PDE-5 | Phosphodiesterase | PDE-5 inhibitors show molecular interactions with lipid-related targets |
| FXR | Nuclear receptor | Regulates bile acid and lipid metabolism; potential regulator of absorption |
| PPARα | Nuclear receptor | Modulates fatty acid oxidation and transport; may influence absorption |
How Is positive regulation of intestinal lipid absorption Regulated?
Positive regulation of intestinal lipid absorption is controlled by a complex network of endocrine, immune, and microbial signals. Adipocyte iron levels act via a fat-gut crosstalk to regulate absorption and mediate protection from obesity. T cell cholesterol transport links intestinal immune responses to dietary lipid absorption, suggesting that immune cells can directly modulate enterocyte lipid handling. Gut microbial metabolites, such as short-chain fatty acids and conjugated linoleic acid, influence intraepithelial T cells and lipid absorption. Additionally, dietary fiber can alter the gut microbiota and their metabolites, indirectly affecting lipid absorption. These regulatory mechanisms are potential targets for therapeutic intervention in metabolic diseases.
positive regulation of intestinal lipid absorption and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CD36 | Obesity, insulin resistance | Knockout mouse, enterocyte-specific KO |
| APOB | Abetalipoproteinemia, cardiovascular disease | Knock-in of patient mutations in mice |
| NPC1L1 | Hypercholesterolemia | Knockout and overexpression in cell lines |
| T cells (CD4+) | Inflammatory bowel disease, metabolic syndrome | T cell-specific knockout mice |
| Adipocyte iron regulators | Obesity | Adipocyte-specific knockout or overexpression |
Obesity and Metabolic Syndrome
Enhanced intestinal lipid absorption contributes to positive energy balance and obesity. Adipocyte iron levels impinge on a fat-gut crosstalk to regulate intestinal lipid absorption and mediate protection from obesity, suggesting that dysregulation of this crosstalk promotes adiposity. Targeting positive regulators of absorption could reduce fat uptake and combat obesity.
Cardiovascular Disease and Dyslipidemia
Increased absorption of cholesterol and fatty acids elevates circulating lipids, a risk factor for atherosclerosis. Antilipemic agents often target intestinal lipid absorption, and understanding positive regulation can inform new therapies. NPC1L1 and ABCG5/ABCG8 are key players in cholesterol absorption and are linked to cardiovascular risk.
Inflammatory Bowel Disease and Colitis-Associated Cancer
Immune cell-derived signals modulate lipid absorption, linking inflammation to metabolic dysfunction. Berberine regulates short-chain fatty acid metabolism and alleviates colitis-associated colorectal tumorigenesis through remodeling intestinal flora, indicating that microbial modulation of lipid absorption may affect cancer risk.
Cystic Fibrosis and Other Malabsorption Disorders
In cystic fibrosis, lumacaftor/ivacaftor improves liver cholesterol metabolism but does not influence hypocholesterolemia, highlighting complex regulation of lipid absorption in disease. Understanding positive regulation may help address malabsorption in such conditions.
From positive regulation of intestinal lipid absorption-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X positively regulate intestinal lipid absorption? | Knockout mouse or enterocyte-specific KO |
| Does a point mutation in gene Y alter lipid absorption? | Point-mutation knock-in mouse |
| Does overexpression of gene Z enhance lipid uptake? | Transgenic overexpression or viral delivery |
| What is the role of a specific protein domain? | Domain-specific knock-in or deletion |
| How does a tagged protein localize during absorption? | Tagged knock-in (e.g., GFP) for imaging |
| Can a candidate gene be targeted for therapy? | CRISPR library screening in enterocyte cell lines |
How to Study the positive regulation of intestinal lipid absorption Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Oral fat tolerance test | Systemic lipid appearance | In vivo assessment of absorption rate |
| Radiolabeled lipid uptake | Enterocyte uptake and transport | In vitro and ex vivo studies |
| RNA-seq | Gene expression changes | Identifying regulators of absorption |
| Proteomics | Protein abundance and modifications | Discovering novel players |
| 16S rRNA sequencing | Microbial composition | Linking microbiota to absorption |
| Metabolomics | Metabolite profiles | Identifying microbial metabolites affecting absorption |
| CRISPR library screening | Gene function at scale | High-throughput discovery of regulators |
Genetic Knockout and Knock-in Models
CRISPR-Cas9 mediated knockout of candidate genes in mice or cell lines allows assessment of their necessity for intestinal lipid absorption. Knock-in of point mutations can mimic human variants. These models are essential for causal inference.
Lipid Absorption Assays
In vivo lipid absorption can be measured using oral fat tolerance tests, radiolabeled lipids, or stable isotopes. In vitro, enterocyte cell lines (e.g., Caco-2) can be used to measure fatty acid uptake and chylomicron secretion.
Transcriptomics and Proteomics
RNA-seq and proteomics of enterocytes after genetic or pharmacological manipulation can identify pathways that positively regulate lipid absorption. Integration with GO enrichment can highlight GO:1904731.
Microbiome and Metabolomics
16S rRNA sequencing and metabolomics can reveal microbial influences on lipid absorption. Berberine's effects on SCFA metabolism and gut flora illustrate this approach.
How CRISPR Can Be Used to Study GO:1904731 positive regulation of intestinal lipid absorption
Knockout
CRISPR knockout of candidate genes in enterocyte cell lines or mouse models can determine whether a gene is required for positive regulation of intestinal lipid absorption. For example, knockout of CD36 or DGAT1 reduces lipid uptake.
Point Mutation
Introducing disease-associated point mutations (e.g., in APOB or NPC1L1) via CRISPR can model human variants and assess their impact on lipid absorption.
Knock-in
Knock-in of reporter tags (e.g., GFP) or humanized alleles allows visualization and functional analysis of proteins involved in lipid absorption in vivo.
Overexpression
CRISPR activation (CRISPRa) or transgenic overexpression can test whether increasing a gene's activity enhances intestinal lipid absorption, identifying positive regulators.
How EDITGENE Supports positive regulation of intestinal lipid absorption Research
Researchers studying positive regulation of intestinal lipid absorption-related genes often need to determine whether a candidate gene is causally involved in enhancing lipid uptake or transport. EDITGENE provides comprehensive CRISPR-based services to accelerate this discovery.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of intestinal lipid absorption research.
Frequently Asked Questions About positive regulation of intestinal lipid absorption
What is GO:1904731?
GO:1904731 is a Gene Ontology term for any process that activates or increases the frequency, rate or extent of intestinal lipid absorption.
What genes are involved in positive regulation of intestinal lipid absorption?
Key genes include CD36, FATP4, APOB, MTTP, DGAT1, MGAT2, NPC1L1, and ABCG5/ABCG8, as well as immune and adipocyte-derived signals.
How is intestinal lipid absorption regulated?
It is regulated by endocrine, immune, and microbial signals, including T cell cholesterol transport, adipocyte iron levels, and gut microbial metabolites.
What diseases are associated with dysregulated intestinal lipid absorption?
Obesity, metabolic syndrome, cardiovascular disease, inflammatory bowel disease, and cystic fibrosis.
What experimental models are used to study positive regulation of intestinal lipid absorption?
Knockout mice, enterocyte cell lines, knock-in models, and CRISPR screens are commonly used.
How can CRISPR help study GO:1904731?
CRISPR knockout, point mutation, knock-in, and overexpression can causally test the role of specific genes in enhancing lipid absorption.
What is the role of T cells in intestinal lipid absorption?
T cell cholesterol transport links intestinal immune responses to dietary lipid absorption, modulating absorption efficiency.
How do adipocytes influence intestinal lipid absorption?
Adipocyte iron levels impinge on a fat-gut crosstalk to regulate intestinal lipid absorption and mediate protection from obesity.
Can diet modulate positive regulation of intestinal lipid absorption?
Yes, dietary fiber and microbial metabolites such as short-chain fatty acids can influence absorption.
What methods measure intestinal lipid absorption?
Oral fat tolerance tests, radiolabeled lipid uptake, and chylomicron secretion assays are standard.
Conclusion
GO:1904731, positive regulation of intestinal lipid absorption, is a critical biological process at the interface of nutrition, immunity, and metabolism. Understanding its molecular regulators offers insights into obesity, cardiovascular disease, and inflammatory conditions. CRISPR-based models and multi-omics approaches are powerful tools to dissect this process and identify therapeutic targets. EDITGENE provides end-to-end services to support such research.
References
- 1. Gao Y et al.. 2025. T cell cholesterol transport links intestinal immune responses to dietary lipid absorption.. Science 390(6769):eadt4169 PMID: 41066556
- 2. Zhang Z et al.. 2021. Adipocyte iron levels impinge on a fat-gut crosstalk to regulate intestinal lipid absorption and mediate protection from obesity.. Cell Metab 33(8):1624-1639.e9 PMID: 34174197
- 3. Unknown. 2012. Antilipemic Agents.. PMID: 31643276
- 4. Yan S et al.. 2022. Berberine regulates short-chain fatty acid metabolism and alleviates the colitis-associated colorectal tumorigenesis through remodeling intestinal flora.. Phytomedicine 102:154217 PMID: 35660350
- 5. Han X et al.. 2023. Regulation of dietary fiber on intestinal microorganisms and its effects on animal health.. Anim Nutr 14:356-369 PMID: 37635930
- 6. Gelzo M et al.. 2021. Lumacaftor/ivacaftor improves liver cholesterol metabolism but does not influence hypocholesterolemia in patients with cystic fibrosis.. J Cyst Fibros 20(1):e1-e6 PMID: 32586737
- 7. Song X et al.. 2023. Gut microbial fatty acid isomerization modulates intraepithelial T cells.. Nature 619(7971):837-843 PMID: 37380774
- 8. Sağır S et al.. 2025. Comparison of PDE-5 inhibitors used in erectile dysfunction with some candidate molecules: A study involving molecular docking, ADMET, DFT, biological target, and activity.. BMC Urol 25(1):47 PMID: 40069715
